[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f2O0OTUg8ElxkwNeXCerfW_g5ITU3rWwNrJtd_aOKlnI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":83,"rows":90},"Brown University",[4],278,false,56,9,360633,27,187,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Alcohol Drinking",12,{"name":18,"count":19},"Depression",11,{"name":21,"count":22},"Alcohol Abuse",10,{"name":24,"count":9},"HIV",{"name":26,"count":27},"Alcohol Use Disorder",8,{"name":29,"count":30},"Prostate Cancer",7,{"name":32,"count":30},"Anxiety",{"name":34,"count":30},"Smoking Cessation",[36,41,46,51,56,59,64,69,74,78],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02656706","Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma","2019-03","Ipilumumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03374332","Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed\u002FRefractory Acute Myeloid Leukemia","2023-09-26","Gemtuzumab Ozogamicin",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05480384","Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction","2025-05-05","Nivolumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04933903","BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","2026-06","Ipilimumab",{"nctId":57,"briefTitle":58,"date":54,"intervention":50},"NCT03355976","BrUOG 354 Nivolumab +\u002F- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06998069","Head and Neck Cancer Study Project in the Geriatric Population","2026-06-01","Arm I Carboplatin, Paclitaxel, Pembrolizumab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04135846","Alpha-1 Blockade for Alcohol Use Disorder (AUD)","2026-08-31","Doxazosin",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06555133","Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC","2026-09-01","yttrium-90 radioembolization",{"nctId":75,"briefTitle":76,"date":72,"intervention":77},"NCT05285917","Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa","Hydroxyurea",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05988632","Intranasal Insulin for Treatment of Alcohol Use Disorder","2026-12-31","Regular Human Insulin then Placebo",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,117,141,159,177,230,253,286,325,347,368,386,404,430,448,474,501,522,552,570,588,606,624,642,674,692,710,728,752,777,802,827,873,913,949,989,1025,1076,1098,1120,1144,1162,1187,1214,1232,1250,1275,1300,1326,1344,1362,1385,1413,1442,1460,1478,1496,1520,1546,1570,1596,1614,1638,1662,1686,1704,1722,1740,1758,1781,1806,1833,1856,1880,1898,1916,1939,1964,1988,2014,2032,2059,2077,2095,2113,2138,2156,2181,2204,2229,2247,2272,2296,2314,2340,2358,2376,2394,2412,2439,2457,2480,2498,2523,2541,2570,2588,2615,2647,2665,2683,2708,2732,2754,2779,2797,2815,2841,2859,2877,2895,2918,2942,2966,2990,3023,3051,3075,3093,3111,3134,3152,3175,3200],{"intervention":77,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":113,"NA":115},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":92,"soonestReadout":72},[103],{"nctId":75,"briefTitle":76,"status":104,"phases":105,"primaryCompletion":72,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":112},"RECRUITING",[87],"2027-09-01","2023-11-15",400,[110,111],"Sickle Cell Anemia in Children","Sickle Cell Disease",[77],{"trials":114,"activeCount":96},[],{"trials":116,"activeCount":96},[],{"intervention":63,"totalTrials":92,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":137,"NA":139},{"trials":120,"activeCount":96},[],{"trials":122,"activeCount":96},[],{"trials":124,"activeCount":96},[],{"trials":126,"activeCount":92,"soonestReadout":62},[127],{"nctId":60,"briefTitle":61,"status":104,"phases":128,"primaryCompletion":62,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},[87],"2027-06-01","2025-08-27",20,[133],"Head and Neck Neoplasms",[63,135,136],"Arm II Carboplatin, Paclitaxel, Cetuximab","Arm III Pembrolizumab",{"trials":138,"activeCount":96},[],{"trials":140,"activeCount":96},[],{"intervention":135,"totalTrials":92,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":155,"NA":157},{"trials":144,"activeCount":96},[],{"trials":146,"activeCount":96},[],{"trials":148,"activeCount":96},[],{"trials":150,"activeCount":92,"soonestReadout":62},[151],{"nctId":60,"briefTitle":61,"status":104,"phases":152,"primaryCompletion":62,"completion":129,"start":130,"enrollment":131,"conditions":153,"interventions":154},[87],[133],[63,135,136],{"trials":156,"activeCount":96},[],{"trials":158,"activeCount":96},[],{"intervention":136,"totalTrials":92,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":173,"NA":175},{"trials":162,"activeCount":96},[],{"trials":164,"activeCount":96},[],{"trials":166,"activeCount":96},[],{"trials":168,"activeCount":92,"soonestReadout":62},[169],{"nctId":60,"briefTitle":61,"status":104,"phases":170,"primaryCompletion":62,"completion":129,"start":130,"enrollment":131,"conditions":171,"interventions":172},[87],[133],[63,135,136],{"trials":174,"activeCount":96},[],{"trials":176,"activeCount":96},[],{"intervention":50,"totalTrials":178,"cells":179},4,{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":181,"activeCount":96},[],{"trials":183,"activeCount":96},[],{"trials":185,"activeCount":178,"soonestReadout":39},[186,194,202,213],{"nctId":37,"briefTitle":38,"status":187,"phases":188,"primaryCompletion":39,"completion":54,"start":189,"enrollment":190,"conditions":191,"interventions":193},"ACTIVE_NOT_RECRUITING",[86],"2016-07",22,[192],"Melanoma",[40,50],{"nctId":52,"briefTitle":53,"status":104,"phases":195,"primaryCompletion":54,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},[86],"2026-09","2021-10-05",25,[200],"Non Small Cell Lung Cancer",[55,50],{"nctId":47,"briefTitle":48,"status":187,"phases":203,"primaryCompletion":49,"completion":204,"start":205,"enrollment":92,"conditions":206,"interventions":211},[86],"2026-05","2023-07-14",[207,208,209,210],"Esophageal Adenocarcinoma","Esophageal Cancer","HER-2 Protein Overexpression","Gastroesophageal-junction Cancer",[50,212],"Trastuzumab deruxtecan",{"nctId":57,"briefTitle":58,"status":187,"phases":214,"primaryCompletion":54,"completion":196,"start":215,"enrollment":216,"conditions":217,"interventions":223},[86],"2018-04-30",46,[218,219,220,221,222],"Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma","Extra Renal Origin","Clear Cell Adenocarcinoma",[50,55],{"trials":225,"activeCount":96},[],{"trials":227,"activeCount":96},[],{"trials":229,"activeCount":96},[],{"intervention":55,"totalTrials":231,"cells":232},2,{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":234,"activeCount":96},[],{"trials":236,"activeCount":96},[],{"trials":238,"activeCount":231,"soonestReadout":54},[239,243],{"nctId":52,"briefTitle":53,"status":104,"phases":240,"primaryCompletion":54,"completion":196,"start":197,"enrollment":198,"conditions":241,"interventions":242},[86],[200],[55,50],{"nctId":57,"briefTitle":58,"status":187,"phases":244,"primaryCompletion":54,"completion":196,"start":215,"enrollment":216,"conditions":245,"interventions":246},[86],[218,219,220,221,222],[50,55],{"trials":248,"activeCount":96},[],{"trials":250,"activeCount":96},[],{"trials":252,"activeCount":96},[],{"intervention":68,"totalTrials":231,"cells":254},{"EARLY_PHASE1":255,"PHASE1":269,"PHASE2":271,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":256,"activeCount":96},[257],{"nctId":258,"briefTitle":259,"status":260,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT01437046","Doxazosin an a1 Antagonist for Alcohol Dependence","COMPLETED",[84],"2013-08-01","2015-03-01","2011-11-01",41,[267,32],"Alcohol Dependence",[68],{"trials":270,"activeCount":96},[],{"trials":272,"activeCount":92,"soonestReadout":67},[273],{"nctId":65,"briefTitle":66,"status":104,"phases":274,"primaryCompletion":67,"completion":67,"start":275,"enrollment":276,"conditions":277,"interventions":279},[86],"2019-12-19",184,[278],"Alcohol Use Disorder (AUD)",[68],{"trials":281,"activeCount":96},[],{"trials":283,"activeCount":96},[],{"trials":285,"activeCount":96},[],{"intervention":287,"totalTrials":231,"cells":288},"Lenalidomide",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":290,"activeCount":96},[],{"trials":292,"activeCount":96},[],{"trials":294,"activeCount":92,"soonestReadout":299},[295,308],{"nctId":296,"briefTitle":297,"status":104,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":306},"NCT04792502","Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",[86],"2027-08-31","2022-07-14",52,[303,304,305],"Follicular Lymphoma","Marginal Zone Lymphoma","B-cell Lymphoma",[307,287],"Mosunetuzumab",{"nctId":309,"briefTitle":310,"status":260,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":265,"conditions":315,"interventions":317},"NCT00717756","Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial",[86],"2013-12","2014-01","2009-01",[316],"Liver Cancer",[318],"lenalidomide",{"trials":320,"activeCount":96},[],{"trials":322,"activeCount":96},[],{"trials":324,"activeCount":96},[],{"intervention":73,"totalTrials":92,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":328,"activeCount":96},[],{"trials":330,"activeCount":96},[],{"trials":332,"activeCount":92,"soonestReadout":72},[333],{"nctId":70,"briefTitle":71,"status":104,"phases":334,"primaryCompletion":72,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},[86],"2029-09-01","2025-04-07",18,[339],"Colorectal Carcinoma Metastatic in the Liver",[73],{"trials":342,"activeCount":96},[],{"trials":344,"activeCount":96},[],{"trials":346,"activeCount":96},[],{"intervention":82,"totalTrials":92,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":96},[],{"trials":354,"activeCount":92,"soonestReadout":81},[355],{"nctId":79,"briefTitle":80,"status":104,"phases":356,"primaryCompletion":81,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},[85,86],"2027-01-31","2025-02-25",40,[26],[82],{"trials":363,"activeCount":96},[],{"trials":365,"activeCount":96},[],{"trials":367,"activeCount":96},[],{"intervention":40,"totalTrials":92,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":371,"activeCount":96},[],{"trials":373,"activeCount":96},[],{"trials":375,"activeCount":92,"soonestReadout":39},[376],{"nctId":37,"briefTitle":38,"status":187,"phases":377,"primaryCompletion":39,"completion":54,"start":189,"enrollment":190,"conditions":378,"interventions":379},[86],[192],[40,50],{"trials":381,"activeCount":96},[],{"trials":383,"activeCount":96},[],{"trials":385,"activeCount":96},[],{"intervention":212,"totalTrials":92,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":389,"activeCount":96},[],{"trials":391,"activeCount":96},[],{"trials":393,"activeCount":92,"soonestReadout":49},[394],{"nctId":47,"briefTitle":48,"status":187,"phases":395,"primaryCompletion":49,"completion":204,"start":205,"enrollment":92,"conditions":396,"interventions":397},[86],[207,208,209,210],[50,212],{"trials":399,"activeCount":96},[],{"trials":401,"activeCount":96},[],{"trials":403,"activeCount":96},[],{"intervention":405,"totalTrials":92,"cells":406},"Rucaparib",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":424,"PHASE4":426,"NA":428},{"trials":408,"activeCount":96},[],{"trials":410,"activeCount":96},[],{"trials":412,"activeCount":92,"soonestReadout":417},[413],{"nctId":414,"briefTitle":415,"status":187,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":422},"NCT04253262","A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer",[85,86],"2027-01","2020-04-03",13,[421],"Metastatic Castration-resistant Prostate Cancer",[405,423],"Copanlisib",{"trials":425,"activeCount":96},[],{"trials":427,"activeCount":96},[],{"trials":429,"activeCount":96},[],{"intervention":423,"totalTrials":92,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":442,"PHASE4":444,"NA":446},{"trials":433,"activeCount":96},[],{"trials":435,"activeCount":96},[],{"trials":437,"activeCount":92,"soonestReadout":417},[438],{"nctId":414,"briefTitle":415,"status":187,"phases":439,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":440,"interventions":441},[85,86],[421],[405,423],{"trials":443,"activeCount":96},[],{"trials":445,"activeCount":96},[],{"trials":447,"activeCount":96},[],{"intervention":449,"totalTrials":92,"cells":450},"Probenecid Oral",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":452,"activeCount":96},[],{"trials":454,"activeCount":96},[],{"trials":456,"activeCount":92,"soonestReadout":461},[457],{"nctId":458,"briefTitle":459,"status":104,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":467},"NCT07118618","Probenecid Administration for Alcohol Craving and Consumption",[86],"2030-12-31","2026-03-14",120,[278,465,466],"Alcohol Consumption","Craving",[449],{"trials":469,"activeCount":96},[],{"trials":471,"activeCount":96},[],{"trials":473,"activeCount":96},[],{"intervention":475,"totalTrials":92,"cells":476},"Dexamethasone",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":478,"activeCount":96},[],{"trials":480,"activeCount":96},[],{"trials":482,"activeCount":92,"soonestReadout":487},[483],{"nctId":484,"briefTitle":485,"status":104,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":494},"NCT06974604","Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM",[86],"2027-05-31","2029-05-31","2025-10-22",60,[492,493],"Breast Neoplasms","Lung Neoplasms",[475],{"trials":496,"activeCount":96},[],{"trials":498,"activeCount":96},[],{"trials":500,"activeCount":96},[],{"intervention":45,"totalTrials":92,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":504,"activeCount":96},[],{"trials":506,"activeCount":96},[],{"trials":508,"activeCount":92,"soonestReadout":44},[509],{"nctId":42,"briefTitle":43,"status":187,"phases":510,"primaryCompletion":44,"completion":511,"start":512,"enrollment":19,"conditions":513,"interventions":515},[86],"2024-09","2019-12-31",[514],"Acute Myeloid Leukemia",[45],{"trials":517,"activeCount":96},[],{"trials":519,"activeCount":96},[],{"trials":521,"activeCount":96},[],{"intervention":523,"totalTrials":92,"cells":524},"THC-dominant cannabis",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":526,"activeCount":96},[],{"trials":528,"activeCount":96},[],{"trials":530,"activeCount":92,"soonestReadout":535},[531],{"nctId":532,"briefTitle":533,"status":104,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":541},"NCT05389930","Cannabis' Impact on Alcohol Consumption",[86],"2027-03-31","2023-03-16",350,[15,539,540,26],"Cannabis Use","Cannabis",[523,542,543,544,545],"CBD-dominant cannabis","Cannabis placebo","Alcohol","Alcohol placebo",{"trials":547,"activeCount":96},[],{"trials":549,"activeCount":96},[],{"trials":551,"activeCount":96},[],{"intervention":542,"totalTrials":92,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":555,"activeCount":96},[],{"trials":557,"activeCount":96},[],{"trials":559,"activeCount":92,"soonestReadout":535},[560],{"nctId":532,"briefTitle":533,"status":104,"phases":561,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":562,"interventions":563},[86],[15,539,540,26],[523,542,543,544,545],{"trials":565,"activeCount":96},[],{"trials":567,"activeCount":96},[],{"trials":569,"activeCount":96},[],{"intervention":543,"totalTrials":92,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":573,"activeCount":96},[],{"trials":575,"activeCount":96},[],{"trials":577,"activeCount":92,"soonestReadout":535},[578],{"nctId":532,"briefTitle":533,"status":104,"phases":579,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":580,"interventions":581},[86],[15,539,540,26],[523,542,543,544,545],{"trials":583,"activeCount":96},[],{"trials":585,"activeCount":96},[],{"trials":587,"activeCount":96},[],{"intervention":544,"totalTrials":92,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":591,"activeCount":96},[],{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":92,"soonestReadout":535},[596],{"nctId":532,"briefTitle":533,"status":104,"phases":597,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":598,"interventions":599},[86],[15,539,540,26],[523,542,543,544,545],{"trials":601,"activeCount":96},[],{"trials":603,"activeCount":96},[],{"trials":605,"activeCount":96},[],{"intervention":545,"totalTrials":92,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":609,"activeCount":96},[],{"trials":611,"activeCount":96},[],{"trials":613,"activeCount":92,"soonestReadout":535},[614],{"nctId":532,"briefTitle":533,"status":104,"phases":615,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":616,"interventions":617},[86],[15,539,540,26],[523,542,543,544,545],{"trials":619,"activeCount":96},[],{"trials":621,"activeCount":96},[],{"trials":623,"activeCount":96},[],{"intervention":307,"totalTrials":92,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":627,"activeCount":96},[],{"trials":629,"activeCount":96},[],{"trials":631,"activeCount":92,"soonestReadout":299},[632],{"nctId":296,"briefTitle":297,"status":104,"phases":633,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":634,"interventions":635},[86],[303,304,305],[307,287],{"trials":637,"activeCount":96},[],{"trials":639,"activeCount":96},[],{"trials":641,"activeCount":96},[],{"intervention":643,"totalTrials":92,"cells":644},"Tafasitamab",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":646,"activeCount":96},[],{"trials":648,"activeCount":96},[],{"trials":650,"activeCount":92,"soonestReadout":656},[651],{"nctId":652,"briefTitle":653,"status":654,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":664},"NCT07502872","TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","NOT_YET_RECRUITING",[86],"2029-12-01","2026-05-01",30,[660,661,662,663],"Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Lymphoma","Lymphoma, B-Cell",[643,665,666,667],"Polatuzumab vedotin","Glofitamab","Obinutuzumab",{"trials":669,"activeCount":96},[],{"trials":671,"activeCount":96},[],{"trials":673,"activeCount":96},[],{"intervention":665,"totalTrials":92,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":677,"activeCount":96},[],{"trials":679,"activeCount":96},[],{"trials":681,"activeCount":92,"soonestReadout":656},[682],{"nctId":652,"briefTitle":653,"status":654,"phases":683,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":684,"interventions":685},[86],[660,661,662,663],[643,665,666,667],{"trials":687,"activeCount":96},[],{"trials":689,"activeCount":96},[],{"trials":691,"activeCount":96},[],{"intervention":666,"totalTrials":92,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":695,"activeCount":96},[],{"trials":697,"activeCount":96},[],{"trials":699,"activeCount":92,"soonestReadout":656},[700],{"nctId":652,"briefTitle":653,"status":654,"phases":701,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":702,"interventions":703},[86],[660,661,662,663],[643,665,666,667],{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":96},[],{"trials":709,"activeCount":96},[],{"intervention":667,"totalTrials":92,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":713,"activeCount":96},[],{"trials":715,"activeCount":96},[],{"trials":717,"activeCount":92,"soonestReadout":656},[718],{"nctId":652,"briefTitle":653,"status":654,"phases":719,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":720,"interventions":721},[86],[660,661,662,663],[643,665,666,667],{"trials":723,"activeCount":96},[],{"trials":725,"activeCount":96},[],{"trials":727,"activeCount":96},[],{"intervention":729,"totalTrials":92,"cells":730},"Naltrexone 50 Mg",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":750},{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":96},[],{"trials":736,"activeCount":96},[],{"trials":738,"activeCount":96},[],{"trials":740,"activeCount":96},[741],{"nctId":742,"briefTitle":743,"status":260,"phases":744,"completion":745,"enrollment":746,"conditions":747,"interventions":749},"NCT00006203","Naltrexone, Craving, and Drinking",[88],"2005-05",180,[748],"Alcoholism",[729],{"trials":751,"activeCount":96},[],{"intervention":753,"totalTrials":92,"cells":754},"Rasagiline",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":775},{"trials":756,"activeCount":96},[],{"trials":758,"activeCount":96},[],{"trials":760,"activeCount":96},[],{"trials":762,"activeCount":96},[],{"trials":764,"activeCount":96},[765],{"nctId":766,"briefTitle":767,"status":260,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":774},"NCT01382342","The Effect of Rasagiline on Cognition in Parkinson's Disease",[88],"2014-02","2011-06",50,[773],"Parkinson's Disease",[753],{"trials":776,"activeCount":96},[],{"intervention":778,"totalTrials":92,"cells":779},"Nicoderm CQ 21Mg\u002F24Hr Transdermal System",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":798,"NA":800},{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":96},[],{"trials":785,"activeCount":96},[],{"trials":787,"activeCount":96},[788],{"nctId":789,"briefTitle":790,"status":260,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":797},"NCT04994444","Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts",[86,87],"2024-04-30","2021-09-01",49,[796],"Tobacco Use Cessation",[778],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"intervention":803,"totalTrials":92,"cells":804},"Modafinil",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":823,"NA":825},{"trials":806,"activeCount":96},[],{"trials":808,"activeCount":96},[],{"trials":810,"activeCount":96},[],{"trials":812,"activeCount":96},[813],{"nctId":814,"briefTitle":815,"status":260,"phases":816,"completion":817,"start":818,"enrollment":190,"conditions":819,"interventions":822},"NCT01172145","Treatment of Apathy in Alzheimer's Disease With Modafinil",[87],"2007-09","2005-07",[820,821],"Apathy","Alzheimer's Disease",[803],{"trials":824,"activeCount":96},[],{"trials":826,"activeCount":96},[],{"intervention":828,"totalTrials":829,"cells":830},"FOLFOXA",3,{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":832,"activeCount":96},[],{"trials":834,"activeCount":96},[],{"trials":836,"activeCount":96},[837,847,858],{"nctId":838,"briefTitle":839,"status":260,"phases":840,"primaryCompletion":841,"completion":842,"start":843,"enrollment":771,"conditions":844,"interventions":846},"NCT02080221","BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial",[86],"2020-01-09","2022-03-16","2014-08",[845],"Metastatic Pancreatic Cancer",[828],{"nctId":848,"briefTitle":849,"status":260,"phases":850,"primaryCompletion":851,"completion":842,"start":852,"enrollment":853,"conditions":854,"interventions":857},"NCT02578732","FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial",[86],"2019-12-18","2016-07-12",28,[855,856],"Locally Advanced Pancreatic Cancer","Pancreatic Cancer",[828],{"nctId":859,"briefTitle":860,"status":260,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":198,"conditions":865,"interventions":866},"NCT02022033","BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial",[86],"2019-07-23","2022-03-17","2014-02-01",[856],[828],{"trials":868,"activeCount":96},[],{"trials":870,"activeCount":96},[],{"trials":872,"activeCount":96},[],{"intervention":874,"totalTrials":231,"cells":875},"Temozolomide",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":877,"activeCount":96},[],{"trials":879,"activeCount":96},[],{"trials":881,"activeCount":96},[882,896],{"nctId":883,"briefTitle":884,"status":885,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":16,"conditions":890,"interventions":894},"NCT03119064","BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma","TERMINATED",[85,86],"2020-04-10","2021-10-08","2017-11-30",[891,892,893],"Glioblastoma Multiforme","Glioblastoma","GBM",[895,874],"Nanoliposomal Irinotecan",{"nctId":897,"briefTitle":898,"status":260,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":905},"NCT01402063","PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation",[86],"2014-04","2015-06","2011-09",63,[891],[906,874],"PPX",{"trials":908,"activeCount":96},[],{"trials":910,"activeCount":96},[],{"trials":912,"activeCount":96},[],{"intervention":914,"totalTrials":231,"cells":915},"Topiramate",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":917,"activeCount":96},[],{"trials":919,"activeCount":96},[],{"trials":921,"activeCount":96},[922,932],{"nctId":923,"briefTitle":924,"status":260,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT01641445","Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms",[85,86],"2016-05","2017-04-12","2012-07",82,[15],[914],{"nctId":933,"briefTitle":934,"status":260,"phases":935,"primaryCompletion":936,"completion":936,"start":937,"enrollment":938,"conditions":939,"interventions":942},"NCT01110434","Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents",[86],"2012-05","2009-12",66,[940,941],"Cannabis Abuse","Cannabis Dependence",[914],{"trials":944,"activeCount":96},[],{"trials":946,"activeCount":96},[],{"trials":948,"activeCount":96},[],{"intervention":950,"totalTrials":231,"cells":951},"Trastuzumab",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[958,973],{"nctId":959,"briefTitle":960,"status":260,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":968},"NCT02789657","Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.",[86],"2019-11-14","2020-03-27","2016-11-21",32,[967],"Breast Cancer",[969,950,970,971,972],"paclitaxel","Pertuzumab","carboplatin","AC",{"nctId":974,"briefTitle":975,"status":976,"phases":977,"start":978,"enrollment":265,"conditions":979,"interventions":980},"NCT00003797","Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas","UNKNOWN",[86],"1999-03",[856],[981,982],"trastuzumab","gemcitabine hydrochloride",{"trials":984,"activeCount":96},[],{"trials":986,"activeCount":96},[],{"trials":988,"activeCount":96},[],{"intervention":990,"totalTrials":231,"cells":991},"Naltrexone",{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":993,"activeCount":96},[],{"trials":995,"activeCount":96},[],{"trials":997,"activeCount":96},[998,1007],{"nctId":999,"briefTitle":1000,"status":885,"phases":1001,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":30,"conditions":1004,"interventions":1006},"NCT01650350","Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer",[86],"2013-10","2012-11",[192,29,1005],"Renal Cancer",[990],{"nctId":1008,"briefTitle":1009,"status":260,"phases":1010,"primaryCompletion":1011,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1018},"NCT00938886","Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment",[86],"2015-11","2015-12","2009-10",150,[1016,1017],"Hazardous Drinking","Cigarette Smoking",[990],{"trials":1020,"activeCount":96},[],{"trials":1022,"activeCount":96},[],{"trials":1024,"activeCount":96},[],{"intervention":1026,"totalTrials":231,"cells":1027},"Gemcitabine",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1029,"activeCount":96},[],{"trials":1031,"activeCount":96},[],{"trials":1033,"activeCount":96},[1034,1059],{"nctId":1035,"briefTitle":1036,"status":1037,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":96,"conditions":1042,"interventions":1056},"NCT05116800","Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma","WITHDRAWN",[86],"2025-08-01","2030-08","2022-03-01",[1043,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053,1054,1055],"Soft Tissue Sarcoma","Undifferentiated Pleomorphic Sarcoma","Myxofibrosarcoma","Leiomyosarcoma","Liposarcoma","Angiosarcoma","Synovial Sarcoma","Rhabdomyosarcoma","Spindle Cell Sarcoma","High Grade Sarcoma","Bone Sarcoma","Osteosarcoma","Ewing Sarcoma of Bone",[1026,1057,1058],"9-ING-41","Docetaxel",{"nctId":1060,"briefTitle":1061,"status":1037,"phases":1062,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":96,"conditions":1066,"interventions":1069},"NCT04906876","A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas",[86],"2022-07","2025-07","2021-09",[1067,1043,1068,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053],"Sarcoma","Metastatic Sarcoma",[1026,1058,1057],{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":96},[],{"intervention":1057,"totalTrials":231,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1079,"activeCount":96},[],{"trials":1081,"activeCount":96},[],{"trials":1083,"activeCount":96},[1084,1088],{"nctId":1035,"briefTitle":1036,"status":1037,"phases":1085,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":96,"conditions":1086,"interventions":1087},[86],[1043,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053,1054,1055],[1026,1057,1058],{"nctId":1060,"briefTitle":1061,"status":1037,"phases":1089,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":96,"conditions":1090,"interventions":1091},[86],[1067,1043,1068,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053],[1026,1058,1057],{"trials":1093,"activeCount":96},[],{"trials":1095,"activeCount":96},[],{"trials":1097,"activeCount":96},[],{"intervention":1058,"totalTrials":231,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1101,"activeCount":96},[],{"trials":1103,"activeCount":96},[],{"trials":1105,"activeCount":96},[1106,1110],{"nctId":1035,"briefTitle":1036,"status":1037,"phases":1107,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":96,"conditions":1108,"interventions":1109},[86],[1043,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053,1054,1055],[1026,1057,1058],{"nctId":1060,"briefTitle":1061,"status":1037,"phases":1111,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":96,"conditions":1112,"interventions":1113},[86],[1067,1043,1068,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053],[1026,1058,1057],{"trials":1115,"activeCount":96},[],{"trials":1117,"activeCount":96},[],{"trials":1119,"activeCount":96},[],{"intervention":1121,"totalTrials":92,"cells":1122},"Cabazitaxel",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1124,"activeCount":96},[],{"trials":1126,"activeCount":96},[],{"trials":1128,"activeCount":96},[1129],{"nctId":1130,"briefTitle":1131,"status":885,"phases":1132,"primaryCompletion":1133,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1137},"NCT01650285","Cabazitaxel and Radiation For Patients With Prostate Cancer",[86],"2014-07","2013-01",5,[29],[1121],{"trials":1139,"activeCount":96},[],{"trials":1141,"activeCount":96},[],{"trials":1143,"activeCount":96},[],{"intervention":895,"totalTrials":92,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1147,"activeCount":96},[],{"trials":1149,"activeCount":96},[],{"trials":1151,"activeCount":96},[1152],{"nctId":883,"briefTitle":884,"status":885,"phases":1153,"primaryCompletion":887,"completion":888,"start":889,"enrollment":16,"conditions":1154,"interventions":1155},[85,86],[891,892,893],[895,874],{"trials":1157,"activeCount":96},[],{"trials":1159,"activeCount":96},[],{"trials":1161,"activeCount":96},[],{"intervention":1163,"totalTrials":92,"cells":1164},"Lamotrigine",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1166,"activeCount":96},[],{"trials":1168,"activeCount":96},[],{"trials":1170,"activeCount":96},[1171],{"nctId":1172,"briefTitle":1173,"status":260,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1180},"NCT04770493","Enhancing the Effects of Alcohol Treatment With Lamotrigine",[86],"2023-10-24","2024-10-24","2022-01-24",44,[26],[1163],{"trials":1182,"activeCount":96},[],{"trials":1184,"activeCount":96},[],{"trials":1186,"activeCount":96},[],{"intervention":1188,"totalTrials":92,"cells":1189},"Dose level 1 ONC201 625mg",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1191,"activeCount":96},[],{"trials":1193,"activeCount":96},[],{"trials":1195,"activeCount":96},[1196],{"nctId":1197,"briefTitle":1198,"status":885,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":419,"conditions":1203,"interventions":1205},"NCT03791398","BrUOG 379 Phase Ib\u002FII Trial ONC201 + Nivolumab in MSS mCRC",[85,86],"2021-06-16","2021-08-05","2019-11-15",[1204],"Metastatic Colorectal Cancer",[1188,1206,1207],"Dose level 2 ONC201 500mg","Dose level 3 ONC201 375mg",{"trials":1209,"activeCount":96},[],{"trials":1211,"activeCount":96},[],{"trials":1213,"activeCount":96},[],{"intervention":1206,"totalTrials":92,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":96},[],{"trials":1219,"activeCount":96},[],{"trials":1221,"activeCount":96},[1222],{"nctId":1197,"briefTitle":1198,"status":885,"phases":1223,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":419,"conditions":1224,"interventions":1225},[85,86],[1204],[1188,1206,1207],{"trials":1227,"activeCount":96},[],{"trials":1229,"activeCount":96},[],{"trials":1231,"activeCount":96},[],{"intervention":1207,"totalTrials":92,"cells":1233},{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1235,"activeCount":96},[],{"trials":1237,"activeCount":96},[],{"trials":1239,"activeCount":96},[1240],{"nctId":1197,"briefTitle":1198,"status":885,"phases":1241,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":419,"conditions":1242,"interventions":1243},[85,86],[1204],[1188,1206,1207],{"trials":1245,"activeCount":96},[],{"trials":1247,"activeCount":96},[],{"trials":1249,"activeCount":96},[],{"intervention":1251,"totalTrials":92,"cells":1252},"Ixabepilone",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1254,"activeCount":96},[],{"trials":1256,"activeCount":96},[],{"trials":1258,"activeCount":96},[1259],{"nctId":1260,"briefTitle":1261,"status":260,"phases":1262,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1268},"NCT00828308","Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer",[86],"2011-03","2016-12","2009-02",16,[29],[1251],{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":96},[],{"trials":1274,"activeCount":96},[],{"intervention":1276,"totalTrials":92,"cells":1277},"Olaparib Pill",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1279,"activeCount":96},[],{"trials":1281,"activeCount":96},[],{"trials":1283,"activeCount":96},[1284],{"nctId":1285,"briefTitle":1286,"status":885,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":92,"conditions":1291,"interventions":1293},"NCT03432897","BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes",[86],"2020-12-15","2021-12-07","2018-05-25",[29,1292],"Adenocarcinoma of the Prostate",[1276],{"trials":1295,"activeCount":96},[],{"trials":1297,"activeCount":96},[],{"trials":1299,"activeCount":96},[],{"intervention":1301,"totalTrials":92,"cells":1302},"Treatment",{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1304,"activeCount":96},[],{"trials":1306,"activeCount":96},[],{"trials":1308,"activeCount":96},[1309],{"nctId":1310,"briefTitle":1311,"status":885,"phases":1312,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":19,"conditions":1315,"interventions":1317},"NCT01671488","A Phase I\u002FII Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer",[85,86],"2018-02","2013-02",[1316],"Anal Cancer",[1301,1318,1319],"5FU","Mitomycin",{"trials":1321,"activeCount":96},[],{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":96},[],{"intervention":1318,"totalTrials":92,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":96},[],{"trials":1331,"activeCount":96},[],{"trials":1333,"activeCount":96},[1334],{"nctId":1310,"briefTitle":1311,"status":885,"phases":1335,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":19,"conditions":1336,"interventions":1337},[85,86],[1316],[1301,1318,1319],{"trials":1339,"activeCount":96},[],{"trials":1341,"activeCount":96},[],{"trials":1343,"activeCount":96},[],{"intervention":1319,"totalTrials":92,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1347,"activeCount":96},[],{"trials":1349,"activeCount":96},[],{"trials":1351,"activeCount":96},[1352],{"nctId":1310,"briefTitle":1311,"status":885,"phases":1353,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":19,"conditions":1354,"interventions":1355},[85,86],[1316],[1301,1318,1319],{"trials":1357,"activeCount":96},[],{"trials":1359,"activeCount":96},[],{"trials":1361,"activeCount":96},[],{"intervention":1363,"totalTrials":92,"cells":1364},"Nicotine polacrilex",{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1366,"activeCount":96},[],{"trials":1368,"activeCount":96},[],{"trials":1370,"activeCount":96},[1371],{"nctId":1372,"briefTitle":1373,"status":260,"phases":1374,"primaryCompletion":769,"completion":769,"start":1375,"enrollment":938,"conditions":1376,"interventions":1378},"NCT01451814","Development of Positive Psychotherapy for Smoking Cessation",[86],"2011-10",[1377],"Smoking",[1363],{"trials":1380,"activeCount":96},[],{"trials":1382,"activeCount":96},[],{"trials":1384,"activeCount":96},[],{"intervention":1386,"totalTrials":92,"cells":1387},"cellular immunotherapy",{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1389,"activeCount":96},[],{"trials":1391,"activeCount":96},[],{"trials":1393,"activeCount":96},[1394],{"nctId":1395,"briefTitle":1396,"status":885,"phases":1397,"primaryCompletion":901,"completion":901,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1406},"NCT01685606","Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia\u002FLymphoma",[86],"2013-03",6,[1401,1402,1403,1404,1405],"Mantle Cell Lymphoma","Diffuse Large Cell Lymphoma","Burkitts Lymphoma","T Cell Lymphomas","Acute Myeloid Leukemia\u002FAcute Lymphoblastic Leukemia",[1386],{"trials":1408,"activeCount":96},[],{"trials":1410,"activeCount":96},[],{"trials":1412,"activeCount":96},[],{"intervention":1414,"totalTrials":92,"cells":1415},"Bupropion",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1417,"activeCount":96},[],{"trials":1419,"activeCount":96},[],{"trials":1421,"activeCount":96},[1422],{"nctId":1423,"briefTitle":1424,"status":260,"phases":1425,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1432},"NCT00136760","Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia",[86],"2009-03","2003-09",57,[1430,1431],"Schizophrenia and Disorders With Psychotic Features","Tobacco Use Disorder",[1414,1433,1434,1435],"Contingent reinforcement plus placebo","non-contingent reinforcement plus bupropion","Non-contingent reinforcement plus placebo",{"trials":1437,"activeCount":96},[],{"trials":1439,"activeCount":96},[],{"trials":1441,"activeCount":96},[],{"intervention":1433,"totalTrials":92,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1445,"activeCount":96},[],{"trials":1447,"activeCount":96},[],{"trials":1449,"activeCount":96},[1450],{"nctId":1423,"briefTitle":1424,"status":260,"phases":1451,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":1428,"conditions":1452,"interventions":1453},[86],[1430,1431],[1414,1433,1434,1435],{"trials":1455,"activeCount":96},[],{"trials":1457,"activeCount":96},[],{"trials":1459,"activeCount":96},[],{"intervention":1434,"totalTrials":92,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":96},[],{"trials":1465,"activeCount":96},[],{"trials":1467,"activeCount":96},[1468],{"nctId":1423,"briefTitle":1424,"status":260,"phases":1469,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":1428,"conditions":1470,"interventions":1471},[86],[1430,1431],[1414,1433,1434,1435],{"trials":1473,"activeCount":96},[],{"trials":1475,"activeCount":96},[],{"trials":1477,"activeCount":96},[],{"intervention":1435,"totalTrials":92,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":96},[],{"trials":1483,"activeCount":96},[],{"trials":1485,"activeCount":96},[1486],{"nctId":1423,"briefTitle":1424,"status":260,"phases":1487,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":1428,"conditions":1488,"interventions":1489},[86],[1430,1431],[1414,1433,1434,1435],{"trials":1491,"activeCount":96},[],{"trials":1493,"activeCount":96},[],{"trials":1495,"activeCount":96},[],{"intervention":1497,"totalTrials":92,"cells":1498},"Nicotine",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1500,"activeCount":96},[],{"trials":1502,"activeCount":96},[],{"trials":1504,"activeCount":96},[1505],{"nctId":1506,"briefTitle":1507,"status":260,"phases":1508,"primaryCompletion":1509,"completion":1509,"start":900,"enrollment":1510,"conditions":1511,"interventions":1513},"NCT01989507","Very Low-Nicotine Cigarettes in Smokers With SUD",[86],"2021-05-31",250,[1512],"Nicotine Dependence",[1497],{"trials":1515,"activeCount":96},[],{"trials":1517,"activeCount":96},[],{"trials":1519,"activeCount":96},[],{"intervention":1521,"totalTrials":92,"cells":1522},"Pembrolizumab",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1524,"activeCount":96},[],{"trials":1526,"activeCount":96},[],{"trials":1528,"activeCount":96},[1529],{"nctId":1530,"briefTitle":1531,"status":1037,"phases":1532,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":96,"conditions":1536,"interventions":1539},"NCT04129515","NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis",[85,86],"2025-12","2026-01","2025-10-30",[1537,1538],"Metastatic Melanoma","Melanoma Brain Metastasis",[1521],{"trials":1541,"activeCount":96},[],{"trials":1543,"activeCount":96},[],{"trials":1545,"activeCount":96},[],{"intervention":1547,"totalTrials":92,"cells":1548},"Ofatumumab and Bortezomib",{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1550,"activeCount":96},[],{"trials":1552,"activeCount":96},[],{"trials":1554,"activeCount":96},[1555],{"nctId":1556,"briefTitle":1557,"status":885,"phases":1558,"primaryCompletion":1559,"completion":1559,"start":1560,"enrollment":22,"conditions":1561,"interventions":1563},"NCT01119794","Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",[86],"2015-07","2010-07",[1562],"Lymphoma, Non-Hodgkins",[1547],{"trials":1565,"activeCount":96},[],{"trials":1567,"activeCount":96},[],{"trials":1569,"activeCount":96},[],{"intervention":1571,"totalTrials":92,"cells":1572},"THC 7.2%",{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1574,"activeCount":96},[],{"trials":1576,"activeCount":96},[],{"trials":1578,"activeCount":96},[1579],{"nctId":1580,"briefTitle":1581,"status":260,"phases":1582,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":1585,"conditions":1586,"interventions":1588},"NCT02983773","Marijuana's Impact on Alcohol Motivation and Consumption",[86],"2021-07-21","2017-01-23",157,[15,1587],"Marijuana",[1571,1589],"THC 3.1%",{"trials":1591,"activeCount":96},[],{"trials":1593,"activeCount":96},[],{"trials":1595,"activeCount":96},[],{"intervention":1589,"totalTrials":92,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":96},[],{"trials":1601,"activeCount":96},[],{"trials":1603,"activeCount":96},[1604],{"nctId":1580,"briefTitle":1581,"status":260,"phases":1605,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":1585,"conditions":1606,"interventions":1607},[86],[15,1587],[1571,1589],{"trials":1609,"activeCount":96},[],{"trials":1611,"activeCount":96},[],{"trials":1613,"activeCount":96},[],{"intervention":1615,"totalTrials":92,"cells":1616},"Atomoxetine",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1618,"activeCount":96},[],{"trials":1620,"activeCount":96},[],{"trials":1622,"activeCount":96},[1623],{"nctId":1624,"briefTitle":1625,"status":260,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":1629,"conditions":1630,"interventions":1631},"NCT04565288","Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine",[86],"2023-05-16","2021-05-06",42,[26],[1615],{"trials":1633,"activeCount":96},[],{"trials":1635,"activeCount":96},[],{"trials":1637,"activeCount":96},[],{"intervention":1639,"totalTrials":92,"cells":1640},"PPX with cisplatin and radiation",{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1642,"activeCount":96},[],{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[1647],{"nctId":1648,"briefTitle":1649,"status":260,"phases":1650,"primaryCompletion":1651,"completion":1652,"start":1653,"enrollment":359,"conditions":1654,"interventions":1655},"NCT00522795","Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)",[86],"2010-02","2010-04","2007-08",[208],[1639],{"trials":1657,"activeCount":96},[],{"trials":1659,"activeCount":96},[],{"trials":1661,"activeCount":96},[],{"intervention":1663,"totalTrials":92,"cells":1664},"42 mg transdermal nicotine replacement",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1666,"activeCount":96},[],{"trials":1668,"activeCount":96},[],{"trials":1670,"activeCount":96},[1671],{"nctId":1672,"briefTitle":1673,"status":260,"phases":1674,"primaryCompletion":1263,"completion":1263,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1679},"NCT01213524","Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia",[86],"2005-09",75,[1431,1678],"Schizophrenia",[1663],{"trials":1681,"activeCount":96},[],{"trials":1683,"activeCount":96},[],{"trials":1685,"activeCount":96},[],{"intervention":969,"totalTrials":92,"cells":1687},{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1689,"activeCount":96},[],{"trials":1691,"activeCount":96},[],{"trials":1693,"activeCount":96},[1694],{"nctId":959,"briefTitle":960,"status":260,"phases":1695,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":1696,"interventions":1697},[86],[967],[969,950,970,971,972],{"trials":1699,"activeCount":96},[],{"trials":1701,"activeCount":96},[],{"trials":1703,"activeCount":96},[],{"intervention":970,"totalTrials":92,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1707,"activeCount":96},[],{"trials":1709,"activeCount":96},[],{"trials":1711,"activeCount":96},[1712],{"nctId":959,"briefTitle":960,"status":260,"phases":1713,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":1714,"interventions":1715},[86],[967],[969,950,970,971,972],{"trials":1717,"activeCount":96},[],{"trials":1719,"activeCount":96},[],{"trials":1721,"activeCount":96},[],{"intervention":971,"totalTrials":92,"cells":1723},{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1725,"activeCount":96},[],{"trials":1727,"activeCount":96},[],{"trials":1729,"activeCount":96},[1730],{"nctId":959,"briefTitle":960,"status":260,"phases":1731,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":1732,"interventions":1733},[86],[967],[969,950,970,971,972],{"trials":1735,"activeCount":96},[],{"trials":1737,"activeCount":96},[],{"trials":1739,"activeCount":96},[],{"intervention":972,"totalTrials":92,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":96},[],{"trials":1745,"activeCount":96},[],{"trials":1747,"activeCount":96},[1748],{"nctId":959,"briefTitle":960,"status":260,"phases":1749,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":1750,"interventions":1751},[86],[967],[969,950,970,971,972],{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"intervention":1759,"totalTrials":92,"cells":1760},"Cetuximab,Paclitaxel, Carboplatin",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1762,"activeCount":96},[],{"trials":1764,"activeCount":96},[],{"trials":1766,"activeCount":96},[1767],{"nctId":1768,"briefTitle":1769,"status":260,"phases":1770,"primaryCompletion":1652,"completion":1652,"start":1771,"enrollment":490,"conditions":1772,"interventions":1774},"NCT00439608","Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer",[86],"2004-10",[208,1773],"Gastric Cancer",[1759],{"trials":1776,"activeCount":96},[],{"trials":1778,"activeCount":96},[],{"trials":1780,"activeCount":96},[],{"intervention":1782,"totalTrials":92,"cells":1783},"Durvalumab",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1785,"activeCount":96},[],{"trials":1787,"activeCount":96},[],{"trials":1789,"activeCount":96},[1790],{"nctId":1791,"briefTitle":1792,"status":260,"phases":1793,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":19,"conditions":1797,"interventions":1799},"NCT03589547","Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung",[86],"2024-01-31","2026-02-18","2019-05-13",[1798],"Stage III Non-small-cell Lung Cancer",[1782],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[],{"trials":1805,"activeCount":96},[],{"intervention":1807,"totalTrials":92,"cells":1808},"Metadoxine",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1810,"activeCount":96},[],{"trials":1812,"activeCount":96},[],{"trials":1814,"activeCount":96},[1815],{"nctId":1816,"briefTitle":1817,"status":260,"phases":1818,"primaryCompletion":1819,"completion":1820,"start":1821,"enrollment":1822,"conditions":1823,"interventions":1826},"NCT01504295","A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease",[86],"2015-01","2015-02","2012-04",38,[1824,1825],"Alcoholism,","Alcoholic Liver Disease",[1807],{"trials":1828,"activeCount":96},[],{"trials":1830,"activeCount":96},[],{"trials":1832,"activeCount":96},[],{"intervention":1834,"totalTrials":92,"cells":1835},"Gemcitabine and Capecitabine and Avastin",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1837,"activeCount":96},[],{"trials":1839,"activeCount":96},[],{"trials":1841,"activeCount":96},[1842],{"nctId":1843,"briefTitle":1844,"status":885,"phases":1845,"primaryCompletion":1846,"completion":313,"start":1847,"enrollment":337,"conditions":1848,"interventions":1849},"NCT00462865","Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse",[86],"2012-03","2007-11",[967],[1834],{"trials":1851,"activeCount":96},[],{"trials":1853,"activeCount":96},[],{"trials":1855,"activeCount":96},[],{"intervention":1857,"totalTrials":92,"cells":1858},"Mifepristone 600-mg\u002Fday or placebo for a week",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1860,"activeCount":96},[],{"trials":1862,"activeCount":96},[],{"trials":1864,"activeCount":96},[1865],{"nctId":1866,"briefTitle":1867,"status":260,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":965,"conditions":1871,"interventions":1873},"NCT02243709","Mifepristone for the Prevention of Relapses of Alcohol Drinking",[85,86],"2021-12-21","2014-09",[1872],"Alcohol Use Disorders (AUD)",[1857],{"trials":1875,"activeCount":96},[],{"trials":1877,"activeCount":96},[],{"trials":1879,"activeCount":96},[],{"intervention":982,"totalTrials":92,"cells":1881},{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1883,"activeCount":96},[],{"trials":1885,"activeCount":96},[],{"trials":1887,"activeCount":96},[1888],{"nctId":974,"briefTitle":975,"status":976,"phases":1889,"start":978,"enrollment":265,"conditions":1890,"interventions":1891},[86],[856],[981,982],{"trials":1893,"activeCount":96},[],{"trials":1895,"activeCount":96},[],{"trials":1897,"activeCount":96},[],{"intervention":906,"totalTrials":92,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1901,"activeCount":96},[],{"trials":1903,"activeCount":96},[],{"trials":1905,"activeCount":96},[1906],{"nctId":897,"briefTitle":898,"status":260,"phases":1907,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":1908,"interventions":1909},[86],[891],[906,874],{"trials":1911,"activeCount":96},[],{"trials":1913,"activeCount":96},[],{"trials":1915,"activeCount":96},[],{"intervention":1917,"totalTrials":92,"cells":1918},"Gemcitabine and fractionated cisplatin",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1920,"activeCount":96},[],{"trials":1922,"activeCount":96},[],{"trials":1924,"activeCount":96},[1925],{"nctId":1926,"briefTitle":1927,"status":885,"phases":1928,"primaryCompletion":901,"completion":901,"start":1133,"enrollment":231,"conditions":1929,"interventions":1932},"NCT02030574","Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin",[86],[1930,1931],"Invasive Bladder Cancer","Bladder Cancer",[1917],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[],{"trials":1938,"activeCount":96},[],{"intervention":1940,"totalTrials":92,"cells":1941},"Cannabis: placebo and medium THC\u002Fmedium CBD",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1943,"activeCount":96},[],{"trials":1945,"activeCount":96},[],{"trials":1947,"activeCount":96},[1948],{"nctId":1949,"briefTitle":1950,"status":885,"phases":1951,"primaryCompletion":1952,"completion":1952,"start":1953,"enrollment":829,"conditions":1954,"interventions":1957},"NCT04269993","Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis",[86],"2023-07-31","2022-05-18",[1955,1956],"Rheumatoid Arthritis","Psoriatic Arthritis",[1940],{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":96},[],{"trials":1963,"activeCount":96},[],{"intervention":1965,"totalTrials":92,"cells":1966},"chemotherapy",{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1968,"activeCount":96},[],{"trials":1970,"activeCount":96},[],{"trials":1972,"activeCount":96},[1973],{"nctId":1974,"briefTitle":1975,"status":885,"phases":1976,"primaryCompletion":1651,"completion":1652,"start":1977,"enrollment":9,"conditions":1978,"interventions":1981},"NCT00740181","Decitabine, Cytarabine, GCSF for Refractory AML\u002FMDS",[86],"2008-08",[1979,1980],"Myelodysplasia","Leukemia",[1965],{"trials":1983,"activeCount":96},[],{"trials":1985,"activeCount":96},[],{"trials":1987,"activeCount":96},[],{"intervention":1989,"totalTrials":92,"cells":1990},"filgrastim",{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1992,"activeCount":96},[],{"trials":1994,"activeCount":96},[],{"trials":1996,"activeCount":96},[1997],{"nctId":1998,"briefTitle":1999,"status":976,"phases":2000,"start":2001,"enrollment":2002,"conditions":2003,"interventions":2006},"NCT00003296","Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer",[86],"1998-01",26,[2004,2005,316],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[1989,2007],"pegylated liposomal doxorubicin hydrochloride",{"trials":2009,"activeCount":96},[],{"trials":2011,"activeCount":96},[],{"trials":2013,"activeCount":96},[],{"intervention":2007,"totalTrials":92,"cells":2015},{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2017,"activeCount":96},[],{"trials":2019,"activeCount":96},[],{"trials":2021,"activeCount":96},[2022],{"nctId":1998,"briefTitle":1999,"status":976,"phases":2023,"start":2001,"enrollment":2002,"conditions":2024,"interventions":2025},[86],[2004,2005,316],[1989,2007],{"trials":2027,"activeCount":96},[],{"trials":2029,"activeCount":96},[],{"trials":2031,"activeCount":96},[],{"intervention":2033,"totalTrials":92,"cells":2034},"Nivolumab induction",{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2036,"activeCount":96},[],{"trials":2038,"activeCount":96},[],{"trials":2040,"activeCount":96},[2041],{"nctId":2042,"briefTitle":2043,"status":885,"phases":2044,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":178,"conditions":2047,"interventions":2049},"NCT03527264","BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer",[86],"2020-11-13","2018-11-08",[2048],"Cervical Cancer",[2033,2050,2051,2052],"Cisplatin","Nivolumab with chemoradiation","Nivolumab maintenance",{"trials":2054,"activeCount":96},[],{"trials":2056,"activeCount":96},[],{"trials":2058,"activeCount":96},[],{"intervention":2050,"totalTrials":92,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2062,"activeCount":96},[],{"trials":2064,"activeCount":96},[],{"trials":2066,"activeCount":96},[2067],{"nctId":2042,"briefTitle":2043,"status":885,"phases":2068,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":178,"conditions":2069,"interventions":2070},[86],[2048],[2033,2050,2051,2052],{"trials":2072,"activeCount":96},[],{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"intervention":2051,"totalTrials":92,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2080,"activeCount":96},[],{"trials":2082,"activeCount":96},[],{"trials":2084,"activeCount":96},[2085],{"nctId":2042,"briefTitle":2043,"status":885,"phases":2086,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":178,"conditions":2087,"interventions":2088},[86],[2048],[2033,2050,2051,2052],{"trials":2090,"activeCount":96},[],{"trials":2092,"activeCount":96},[],{"trials":2094,"activeCount":96},[],{"intervention":2052,"totalTrials":92,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2098,"activeCount":96},[],{"trials":2100,"activeCount":96},[],{"trials":2102,"activeCount":96},[2103],{"nctId":2042,"briefTitle":2043,"status":885,"phases":2104,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":178,"conditions":2105,"interventions":2106},[86],[2048],[2033,2050,2051,2052],{"trials":2108,"activeCount":96},[],{"trials":2110,"activeCount":96},[],{"trials":2112,"activeCount":96},[],{"intervention":2114,"totalTrials":92,"cells":2115},"Very Low Nicotine Content Cigarettes",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2117,"activeCount":96},[],{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[2122],{"nctId":2123,"briefTitle":2124,"status":260,"phases":2125,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":1428,"conditions":2128,"interventions":2130},"NCT03860077","Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco",[85,86],"2022-03-23","2019-10-10",[2129],"Nicotine Dependence, Cigarettes, Uncomplicated",[2114,2131],"Normal Nicotine Content Cigarettes",{"trials":2133,"activeCount":96},[],{"trials":2135,"activeCount":96},[],{"trials":2137,"activeCount":96},[],{"intervention":2131,"totalTrials":92,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2141,"activeCount":96},[],{"trials":2143,"activeCount":96},[],{"trials":2145,"activeCount":96},[2146],{"nctId":2123,"briefTitle":2124,"status":260,"phases":2147,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":1428,"conditions":2148,"interventions":2149},[85,86],[2129],[2114,2131],{"trials":2151,"activeCount":96},[],{"trials":2153,"activeCount":96},[],{"trials":2155,"activeCount":96},[],{"intervention":2157,"totalTrials":92,"cells":2158},"Smoked marijuana cigarettes: High THC dose",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2175,"PHASE4":2177,"NA":2179},{"trials":2160,"activeCount":96},[],{"trials":2162,"activeCount":96},[],{"trials":2164,"activeCount":96},[2165],{"nctId":2166,"briefTitle":2167,"status":260,"phases":2168,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2174},"NCT03518567","Behavioral Economic Analysis of Demand for Marijuana",[86],"2021-05-24","2018-10-15",133,[2173],"Marijuana Smoking",[2157],{"trials":2176,"activeCount":96},[],{"trials":2178,"activeCount":96},[],{"trials":2180,"activeCount":96},[],{"intervention":2182,"totalTrials":92,"cells":2183},"Aflibercept",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2185,"activeCount":96},[],{"trials":2187,"activeCount":96},[],{"trials":2189,"activeCount":96},[2190],{"nctId":2191,"briefTitle":2192,"status":885,"phases":2193,"primaryCompletion":1012,"completion":2194,"start":2195,"enrollment":22,"conditions":2196,"interventions":2197},"NCT01669720","Adjuvant Aflibercept for Metastatic Colorectal Cancer",[86],"2016-01","2012-12",[1204],[2182],{"trials":2199,"activeCount":96},[],{"trials":2201,"activeCount":96},[],{"trials":2203,"activeCount":96},[],{"intervention":2205,"totalTrials":92,"cells":2206},"Methotrexate",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2208,"activeCount":96},[],{"trials":2210,"activeCount":96},[],{"trials":2212,"activeCount":96},[2213],{"nctId":2214,"briefTitle":2215,"status":1037,"phases":2216,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":96,"conditions":2220,"interventions":2221},"NCT03719560","Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma",[86],"2022-12-31","2025-12-31","2019-07-01",[660],[2205,2222],"Cytarabine",{"trials":2224,"activeCount":96},[],{"trials":2226,"activeCount":96},[],{"trials":2228,"activeCount":96},[],{"intervention":2222,"totalTrials":92,"cells":2230},{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2232,"activeCount":96},[],{"trials":2234,"activeCount":96},[],{"trials":2236,"activeCount":96},[2237],{"nctId":2214,"briefTitle":2215,"status":1037,"phases":2238,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":96,"conditions":2239,"interventions":2240},[86],[660],[2205,2222],{"trials":2242,"activeCount":96},[],{"trials":2244,"activeCount":96},[],{"trials":2246,"activeCount":96},[],{"intervention":2248,"totalTrials":92,"cells":2249},"intervention",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2266,"PHASE4":2268,"NA":2270},{"trials":2251,"activeCount":96},[],{"trials":2253,"activeCount":96},[],{"trials":2255,"activeCount":96},[2256],{"nctId":2257,"briefTitle":2258,"status":885,"phases":2259,"primaryCompletion":2260,"completion":2261,"start":2262,"enrollment":1135,"conditions":2263,"interventions":2265},"NCT01057017","First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras",[86],"2011-04","2011-12","2010-01",[2264],"Colorectal Cancer",[2248],{"trials":2267,"activeCount":96},[],{"trials":2269,"activeCount":96},[],{"trials":2271,"activeCount":96},[],{"intervention":2273,"totalTrials":92,"cells":2274},"Baclofen",{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2276,"activeCount":96},[],{"trials":2278,"activeCount":96},[],{"trials":2280,"activeCount":96},[2281],{"nctId":2282,"briefTitle":2283,"status":260,"phases":2284,"primaryCompletion":1652,"completion":2285,"start":937,"enrollment":2286,"conditions":2287,"interventions":2288},"NCT01076283","A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking",[86],"2010-05",14,[748],[2273,2289],"Cyproheptadine",{"trials":2291,"activeCount":96},[],{"trials":2293,"activeCount":96},[],{"trials":2295,"activeCount":96},[],{"intervention":2289,"totalTrials":92,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2299,"activeCount":96},[],{"trials":2301,"activeCount":96},[],{"trials":2303,"activeCount":96},[2304],{"nctId":2282,"briefTitle":2283,"status":260,"phases":2305,"primaryCompletion":1652,"completion":2285,"start":937,"enrollment":2286,"conditions":2306,"interventions":2307},[86],[748],[2273,2289],{"trials":2309,"activeCount":96},[],{"trials":2311,"activeCount":96},[],{"trials":2313,"activeCount":96},[],{"intervention":2315,"totalTrials":92,"cells":2316},"Gemcitabine 1000mg\u002Fm2 30 minutes",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2318,"activeCount":96},[],{"trials":2320,"activeCount":96},[2321],{"nctId":2322,"briefTitle":2323,"status":885,"phases":2324,"primaryCompletion":1977,"completion":1977,"start":2325,"enrollment":198,"conditions":2326,"interventions":2327},"NCT00447122","BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer",[85],"2007-03",[845],[2315,2328,2329,2330,2331],"Lapatinib 1000mg\u002Fd","Lapatinib 1500mg\u002Fd","Gemcitabine 1000mg\u002Fm2 100minutes","Oxaliplatin 100mg\u002Fm2",{"trials":2333,"activeCount":96},[],{"trials":2335,"activeCount":96},[],{"trials":2337,"activeCount":96},[],{"trials":2339,"activeCount":96},[],{"intervention":2328,"totalTrials":92,"cells":2341},{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2356},{"trials":2343,"activeCount":96},[],{"trials":2345,"activeCount":96},[2346],{"nctId":2322,"briefTitle":2323,"status":885,"phases":2347,"primaryCompletion":1977,"completion":1977,"start":2325,"enrollment":198,"conditions":2348,"interventions":2349},[85],[845],[2315,2328,2329,2330,2331],{"trials":2351,"activeCount":96},[],{"trials":2353,"activeCount":96},[],{"trials":2355,"activeCount":96},[],{"trials":2357,"activeCount":96},[],{"intervention":2329,"totalTrials":92,"cells":2359},{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2374},{"trials":2361,"activeCount":96},[],{"trials":2363,"activeCount":96},[2364],{"nctId":2322,"briefTitle":2323,"status":885,"phases":2365,"primaryCompletion":1977,"completion":1977,"start":2325,"enrollment":198,"conditions":2366,"interventions":2367},[85],[845],[2315,2328,2329,2330,2331],{"trials":2369,"activeCount":96},[],{"trials":2371,"activeCount":96},[],{"trials":2373,"activeCount":96},[],{"trials":2375,"activeCount":96},[],{"intervention":2330,"totalTrials":92,"cells":2377},{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2379,"activeCount":96},[],{"trials":2381,"activeCount":96},[2382],{"nctId":2322,"briefTitle":2323,"status":885,"phases":2383,"primaryCompletion":1977,"completion":1977,"start":2325,"enrollment":198,"conditions":2384,"interventions":2385},[85],[845],[2315,2328,2329,2330,2331],{"trials":2387,"activeCount":96},[],{"trials":2389,"activeCount":96},[],{"trials":2391,"activeCount":96},[],{"trials":2393,"activeCount":96},[],{"intervention":2331,"totalTrials":92,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2397,"activeCount":96},[],{"trials":2399,"activeCount":96},[2400],{"nctId":2322,"briefTitle":2323,"status":885,"phases":2401,"primaryCompletion":1977,"completion":1977,"start":2325,"enrollment":198,"conditions":2402,"interventions":2403},[85],[845],[2315,2328,2329,2330,2331],{"trials":2405,"activeCount":96},[],{"trials":2407,"activeCount":96},[],{"trials":2409,"activeCount":96},[],{"trials":2411,"activeCount":96},[],{"intervention":2413,"totalTrials":92,"cells":2414},"Degarelix",{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2431,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2416,"activeCount":96},[],{"trials":2418,"activeCount":96},[2419],{"nctId":2420,"briefTitle":2421,"status":885,"phases":2422,"primaryCompletion":2423,"completion":2424,"start":2425,"enrollment":231,"conditions":2426,"interventions":2429},"NCT05839119","Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant",[85],"2025-07-01","2025-10-17","2023-10-02",[2427,2428],"Urothelial Carcinoma Bladder","Androgen Receptor Positive",[2413,2430],"Gemcitabine\u002FCisplatin",{"trials":2432,"activeCount":96},[],{"trials":2434,"activeCount":96},[],{"trials":2436,"activeCount":96},[],{"trials":2438,"activeCount":96},[],{"intervention":2430,"totalTrials":92,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":96},[],{"trials":2444,"activeCount":96},[2445],{"nctId":2420,"briefTitle":2421,"status":885,"phases":2446,"primaryCompletion":2423,"completion":2424,"start":2425,"enrollment":231,"conditions":2447,"interventions":2448},[85],[2427,2428],[2413,2430],{"trials":2450,"activeCount":96},[],{"trials":2452,"activeCount":96},[],{"trials":2454,"activeCount":96},[],{"trials":2456,"activeCount":96},[],{"intervention":2458,"totalTrials":92,"cells":2459},"Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2461,"activeCount":96},[],{"trials":2463,"activeCount":96},[2464],{"nctId":2465,"briefTitle":2466,"status":885,"phases":2467,"primaryCompletion":1263,"completion":2261,"start":1426,"enrollment":19,"conditions":2468,"interventions":2470},"NCT00787852","A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)",[85],[2469],"Non-Small Cell Lung Cancer",[2458,2471],"Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38",{"trials":2473,"activeCount":96},[],{"trials":2475,"activeCount":96},[],{"trials":2477,"activeCount":96},[],{"trials":2479,"activeCount":96},[],{"intervention":2471,"totalTrials":92,"cells":2481},{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2483,"activeCount":96},[],{"trials":2485,"activeCount":96},[2486],{"nctId":2465,"briefTitle":2466,"status":885,"phases":2487,"primaryCompletion":1263,"completion":2261,"start":1426,"enrollment":19,"conditions":2488,"interventions":2489},[85],[2469],[2458,2471],{"trials":2491,"activeCount":96},[],{"trials":2493,"activeCount":96},[],{"trials":2495,"activeCount":96},[],{"trials":2497,"activeCount":96},[],{"intervention":2499,"totalTrials":92,"cells":2500},"Abemaciclib",{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2502,"activeCount":96},[],{"trials":2504,"activeCount":96},[2505],{"nctId":2506,"briefTitle":2507,"status":885,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":829,"conditions":2511,"interventions":2513},"NCT03905889","A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma",[85],"2022-03-08","2019-06-05",[2512],"Renal Cell Carcinoma Metastatic",[2499,2514],"Sunitinib",{"trials":2516,"activeCount":96},[],{"trials":2518,"activeCount":96},[],{"trials":2520,"activeCount":96},[],{"trials":2522,"activeCount":96},[],{"intervention":2514,"totalTrials":92,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2533,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":96},[],{"trials":2528,"activeCount":96},[2529],{"nctId":2506,"briefTitle":2507,"status":885,"phases":2530,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":829,"conditions":2531,"interventions":2532},[85],[2512],[2499,2514],{"trials":2534,"activeCount":96},[],{"trials":2536,"activeCount":96},[],{"trials":2538,"activeCount":96},[],{"trials":2540,"activeCount":96},[],{"intervention":2542,"totalTrials":92,"cells":2543},"Palbociclib Oral Product",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2562,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2545,"activeCount":96},[],{"trials":2547,"activeCount":96},[2548],{"nctId":2549,"briefTitle":2550,"status":1037,"phases":2551,"primaryCompletion":2552,"completion":2552,"start":2553,"enrollment":96,"conditions":2554,"interventions":2560},"NCT05655598","TAS-116 Plus Palbociclib in Breast and Rb-null Cancer",[85],"2024-08-05","2023-09-12",[2555,2556,2557,2558,1043,2559,1931],"Advanced Breast Cancer","Treatment-Refractory Solid Tumors","Retinoblastoma Deficiency","SCLC","Endometrial Cancer",[2542,2561,2561,2561],"TAS-116",{"trials":2563,"activeCount":96},[],{"trials":2565,"activeCount":96},[],{"trials":2567,"activeCount":96},[],{"trials":2569,"activeCount":96},[],{"intervention":2561,"totalTrials":92,"cells":2571},{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2580,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2573,"activeCount":96},[],{"trials":2575,"activeCount":96},[2576],{"nctId":2549,"briefTitle":2550,"status":1037,"phases":2577,"primaryCompletion":2552,"completion":2552,"start":2553,"enrollment":96,"conditions":2578,"interventions":2579},[85],[2555,2556,2557,2558,1043,2559,1931],[2542,2561,2561,2561],{"trials":2581,"activeCount":96},[],{"trials":2583,"activeCount":96},[],{"trials":2585,"activeCount":96},[],{"trials":2587,"activeCount":96},[],{"intervention":2589,"totalTrials":92,"cells":2590},"Talazoparib Oral",{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2592,"activeCount":96},[],{"trials":2594,"activeCount":96},[2595],{"nctId":2596,"briefTitle":2597,"status":885,"phases":2598,"primaryCompletion":2599,"completion":2600,"start":2601,"enrollment":92,"conditions":2602,"interventions":2606},"NCT04598321","BrUOG 390: Neoadjuvant Treatment With Talazoparib",[85],"2022-11-30","2022-12-06","2021-03-29",[2603,2604,218,219,2605],"BRCA1 Mutation","BRCA2 Mutation","High Grade Serous Carcinoma",[2589],{"trials":2608,"activeCount":96},[],{"trials":2610,"activeCount":96},[],{"trials":2612,"activeCount":96},[],{"trials":2614,"activeCount":96},[],{"intervention":2616,"totalTrials":92,"cells":2617},"Rituximab",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2639,"PHASE3":2641,"PHASE4":2643,"NA":2645},{"trials":2619,"activeCount":96},[],{"trials":2621,"activeCount":96},[2622],{"nctId":2623,"briefTitle":2624,"status":260,"phases":2625,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":19,"conditions":2629,"interventions":2636},"NCT02257242","Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma",[85],"2020-08-22","2020-11-18","2017-05-10",[2630,2631,2632,2633,2634,2635],"Lymphoma, Non-Hodgkin","Lymphoma, Follicular","Lymphoma, Mantle-Cell","Lymphoma, Small-Cell","Waldenstrom Macroglobulinemia","Lymphoma, B-Cell, Marginal Zone",[2616,2637,2638],"Bendamustine","Vincristine sulfate liposome",{"trials":2640,"activeCount":96},[],{"trials":2642,"activeCount":96},[],{"trials":2644,"activeCount":96},[],{"trials":2646,"activeCount":96},[],{"intervention":2637,"totalTrials":92,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2657,"PHASE3":2659,"PHASE4":2661,"NA":2663},{"trials":2650,"activeCount":96},[],{"trials":2652,"activeCount":96},[2653],{"nctId":2623,"briefTitle":2624,"status":260,"phases":2654,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":19,"conditions":2655,"interventions":2656},[85],[2630,2631,2632,2633,2634,2635],[2616,2637,2638],{"trials":2658,"activeCount":96},[],{"trials":2660,"activeCount":96},[],{"trials":2662,"activeCount":96},[],{"trials":2664,"activeCount":96},[],{"intervention":2638,"totalTrials":92,"cells":2666},{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2675,"PHASE3":2677,"PHASE4":2679,"NA":2681},{"trials":2668,"activeCount":96},[],{"trials":2670,"activeCount":96},[2671],{"nctId":2623,"briefTitle":2624,"status":260,"phases":2672,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":19,"conditions":2673,"interventions":2674},[85],[2630,2631,2632,2633,2634,2635],[2616,2637,2638],{"trials":2676,"activeCount":96},[],{"trials":2678,"activeCount":96},[],{"trials":2680,"activeCount":96},[],{"trials":2682,"activeCount":96},[],{"intervention":2684,"totalTrials":92,"cells":2685},"intranasal oxytocin, 40 IU, twice a day for 7 days",{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2700,"PHASE3":2702,"PHASE4":2704,"NA":2706},{"trials":2687,"activeCount":96},[],{"trials":2689,"activeCount":96},[2690],{"nctId":2691,"briefTitle":2692,"status":260,"phases":2693,"primaryCompletion":2694,"completion":2695,"start":2696,"enrollment":131,"conditions":2697,"interventions":2699},"NCT04051619","Oxytocin, Stress, Craving, Opioid Use Disorder",[85],"2023-12-22","2023-12-23","2020-01-06",[2698],"Opioid Use Disorder",[2684],{"trials":2701,"activeCount":96},[],{"trials":2703,"activeCount":96},[],{"trials":2705,"activeCount":96},[],{"trials":2707,"activeCount":96},[],{"intervention":2709,"totalTrials":92,"cells":2710},"Oxytocin nasal spray",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2712,"activeCount":96},[],{"trials":2714,"activeCount":96},[2715],{"nctId":2716,"briefTitle":2717,"status":260,"phases":2718,"primaryCompletion":2719,"completion":2719,"start":2720,"enrollment":2721,"conditions":2722,"interventions":2723},"NCT04071119","Alcohol and Cigarette Craving During Oxytocin Treatment",[85],"2024-04-02","2020-11-09",19,[26,1377],[2709],{"trials":2725,"activeCount":96},[],{"trials":2727,"activeCount":96},[],{"trials":2729,"activeCount":96},[],{"trials":2731,"activeCount":96},[],{"intervention":2733,"totalTrials":92,"cells":2734},"Dasatinib",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2746,"PHASE3":2748,"PHASE4":2750,"NA":2752},{"trials":2736,"activeCount":96},[],{"trials":2738,"activeCount":96},[2739],{"nctId":2740,"briefTitle":2741,"status":1037,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":1134,"enrollment":96,"conditions":2744,"interventions":2745},"NCT01826838","Study of Dasatinib, Androgen Deprivation Therapy and Radiation",[85],"2013-04",[29],[2733],{"trials":2747,"activeCount":96},[],{"trials":2749,"activeCount":96},[],{"trials":2751,"activeCount":96},[],{"trials":2753,"activeCount":96},[],{"intervention":2755,"totalTrials":92,"cells":2756},"Dose level 1",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2771,"PHASE3":2773,"PHASE4":2775,"NA":2777},{"trials":2758,"activeCount":96},[],{"trials":2760,"activeCount":96},[2761],{"nctId":2762,"briefTitle":2763,"status":260,"phases":2764,"primaryCompletion":1870,"completion":2765,"start":1003,"enrollment":2766,"conditions":2767,"interventions":2768},"NCT01744353","BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study",[85],"2015-08",35,[845],[2755,2769,2770],"Dose level 2\u002FMTD","Dose level 3",{"trials":2772,"activeCount":96},[],{"trials":2774,"activeCount":96},[],{"trials":2776,"activeCount":96},[],{"trials":2778,"activeCount":96},[],{"intervention":2769,"totalTrials":92,"cells":2780},{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2782,"activeCount":96},[],{"trials":2784,"activeCount":96},[2785],{"nctId":2762,"briefTitle":2763,"status":260,"phases":2786,"primaryCompletion":1870,"completion":2765,"start":1003,"enrollment":2766,"conditions":2787,"interventions":2788},[85],[845],[2755,2769,2770],{"trials":2790,"activeCount":96},[],{"trials":2792,"activeCount":96},[],{"trials":2794,"activeCount":96},[],{"trials":2796,"activeCount":96},[],{"intervention":2770,"totalTrials":92,"cells":2798},{"EARLY_PHASE1":2799,"PHASE1":2801,"PHASE2":2807,"PHASE3":2809,"PHASE4":2811,"NA":2813},{"trials":2800,"activeCount":96},[],{"trials":2802,"activeCount":96},[2803],{"nctId":2762,"briefTitle":2763,"status":260,"phases":2804,"primaryCompletion":1870,"completion":2765,"start":1003,"enrollment":2766,"conditions":2805,"interventions":2806},[85],[845],[2755,2769,2770],{"trials":2808,"activeCount":96},[],{"trials":2810,"activeCount":96},[],{"trials":2812,"activeCount":96},[],{"trials":2814,"activeCount":96},[],{"intervention":2816,"totalTrials":92,"cells":2817},"cohort 1",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2839},{"trials":2819,"activeCount":96},[],{"trials":2821,"activeCount":96},[2822],{"nctId":2823,"briefTitle":2824,"status":260,"phases":2825,"primaryCompletion":2826,"completion":2826,"start":2827,"enrollment":11,"conditions":2828,"interventions":2829},"NCT00439179","A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema",[85],"2007-12","2006-07",[845],[2816,2830,2831,2832],"cohort 2","cohort 3","cohort 4",{"trials":2834,"activeCount":96},[],{"trials":2836,"activeCount":96},[],{"trials":2838,"activeCount":96},[],{"trials":2840,"activeCount":96},[],{"intervention":2830,"totalTrials":92,"cells":2842},{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2851,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2844,"activeCount":96},[],{"trials":2846,"activeCount":96},[2847],{"nctId":2823,"briefTitle":2824,"status":260,"phases":2848,"primaryCompletion":2826,"completion":2826,"start":2827,"enrollment":11,"conditions":2849,"interventions":2850},[85],[845],[2816,2830,2831,2832],{"trials":2852,"activeCount":96},[],{"trials":2854,"activeCount":96},[],{"trials":2856,"activeCount":96},[],{"trials":2858,"activeCount":96},[],{"intervention":2831,"totalTrials":92,"cells":2860},{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2869,"PHASE3":2871,"PHASE4":2873,"NA":2875},{"trials":2862,"activeCount":96},[],{"trials":2864,"activeCount":96},[2865],{"nctId":2823,"briefTitle":2824,"status":260,"phases":2866,"primaryCompletion":2826,"completion":2826,"start":2827,"enrollment":11,"conditions":2867,"interventions":2868},[85],[845],[2816,2830,2831,2832],{"trials":2870,"activeCount":96},[],{"trials":2872,"activeCount":96},[],{"trials":2874,"activeCount":96},[],{"trials":2876,"activeCount":96},[],{"intervention":2832,"totalTrials":92,"cells":2878},{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2880,"activeCount":96},[],{"trials":2882,"activeCount":96},[2883],{"nctId":2823,"briefTitle":2824,"status":260,"phases":2884,"primaryCompletion":2826,"completion":2826,"start":2827,"enrollment":11,"conditions":2885,"interventions":2886},[85],[845],[2816,2830,2831,2832],{"trials":2888,"activeCount":96},[],{"trials":2890,"activeCount":96},[],{"trials":2892,"activeCount":96},[],{"trials":2894,"activeCount":96},[],{"intervention":2896,"totalTrials":92,"cells":2897},"Probenecid or placebo single administration",{"EARLY_PHASE1":2898,"PHASE1":2900,"PHASE2":2910,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2899,"activeCount":96},[],{"trials":2901,"activeCount":96},[2902],{"nctId":2903,"briefTitle":2904,"status":260,"phases":2905,"primaryCompletion":1627,"completion":2906,"start":2907,"enrollment":2766,"conditions":2908,"interventions":2909},"NCT04218357","Probenecid as Medication for Alcohol Use Disorder (PROB)",[85],"2023-05-20","2020-12-02",[26],[2896],{"trials":2911,"activeCount":96},[],{"trials":2913,"activeCount":96},[],{"trials":2915,"activeCount":96},[],{"trials":2917,"activeCount":96},[],{"intervention":2919,"totalTrials":92,"cells":2920},"Ondansetron and Sertraline",{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2934,"PHASE3":2936,"PHASE4":2938,"NA":2940},{"trials":2922,"activeCount":96},[],{"trials":2924,"activeCount":96},[2925],{"nctId":2926,"briefTitle":2927,"status":260,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":2931,"conditions":2932,"interventions":2933},"NCT01113164","Matching Genotypes and Serotonergic Medications for Alcoholism",[85],"2012-02","2008-09",79,[748],[2919],{"trials":2935,"activeCount":96},[],{"trials":2937,"activeCount":96},[],{"trials":2939,"activeCount":96},[],{"trials":2941,"activeCount":96},[],{"intervention":2943,"totalTrials":92,"cells":2944},"L-carnitine",{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2958,"PHASE3":2960,"PHASE4":2962,"NA":2964},{"trials":2946,"activeCount":96},[],{"trials":2948,"activeCount":96},[2949],{"nctId":2950,"briefTitle":2951,"status":260,"phases":2952,"primaryCompletion":2953,"completion":2953,"start":2954,"enrollment":2955,"conditions":2956,"interventions":2957},"NCT05355311","Enhancing the Effects of Alcohol Treatment With L-Carnitine",[85],"2025-05-31","2024-09-27",24,[26],[2943],{"trials":2959,"activeCount":96},[],{"trials":2961,"activeCount":96},[],{"trials":2963,"activeCount":96},[],{"trials":2965,"activeCount":96},[],{"intervention":2967,"totalTrials":92,"cells":2968},"Open Placebo",{"EARLY_PHASE1":2969,"PHASE1":2980,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2970,"activeCount":96},[2971],{"nctId":2972,"briefTitle":2973,"status":260,"phases":2974,"primaryCompletion":2975,"completion":2975,"start":2976,"enrollment":22,"conditions":2977,"interventions":2979},"NCT03631251","Using Honest Placebos to Improve Pain Management in Hand Surgery Patients",[84],"2019-07-15","2018-08-17",[2978],"Hand or Wrist Surgery",[2967],{"trials":2981,"activeCount":96},[],{"trials":2983,"activeCount":96},[],{"trials":2985,"activeCount":96},[],{"trials":2987,"activeCount":96},[],{"trials":2989,"activeCount":96},[],{"intervention":2991,"totalTrials":231,"cells":2992},"Nicotine Replacement Treatment",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2994,"activeCount":96},[],{"trials":2996,"activeCount":96},[],{"trials":2998,"activeCount":96},[],{"trials":3000,"activeCount":96},[],{"trials":3002,"activeCount":96},[],{"trials":3004,"activeCount":96},[3005,3014],{"nctId":3006,"briefTitle":3007,"status":260,"phases":3008,"primaryCompletion":900,"completion":900,"start":3009,"enrollment":3010,"conditions":3011,"interventions":3013},"NCT00807742","Contingency Management for Smoking in Substance Abusers",[89],"2008-10",340,[3012],"Substance Abuse",[2991],{"nctId":3015,"briefTitle":3016,"status":260,"phases":3017,"primaryCompletion":3018,"completion":1870,"start":314,"enrollment":3019,"conditions":3020,"interventions":3021},"NCT00756275","Varenicline and Motivational Advice for Smokers With Substance Use Disorders",[89],"2014-03",158,[34,1512],[2991,3022],"varenicline",{"intervention":3022,"totalTrials":231,"cells":3024},{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3029,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3026,"activeCount":96},[],{"trials":3028,"activeCount":96},[],{"trials":3030,"activeCount":96},[3031],{"nctId":3032,"briefTitle":3033,"status":885,"phases":3034,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":1135,"conditions":3037,"interventions":3039},"NCT03507127","Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1",[86],"2019-06-30","2018-05-01",[3038],"Tobacco Dependence",[3040],"Varenicline",{"trials":3042,"activeCount":96},[],{"trials":3044,"activeCount":96},[],{"trials":3046,"activeCount":96},[3047],{"nctId":3015,"briefTitle":3016,"status":260,"phases":3048,"primaryCompletion":3018,"completion":1870,"start":314,"enrollment":3019,"conditions":3049,"interventions":3050},[89],[34,1512],[2991,3022],{"intervention":3052,"totalTrials":92,"cells":3053},"Injection of Steroid into Foot",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3058,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3055,"activeCount":96},[],{"trials":3057,"activeCount":96},[],{"trials":3059,"activeCount":96},[],{"trials":3061,"activeCount":96},[],{"trials":3063,"activeCount":96},[],{"trials":3065,"activeCount":96},[3066],{"nctId":3067,"briefTitle":3068,"status":976,"phases":3069,"start":745,"enrollment":463,"conditions":3070,"interventions":3072},"NCT00284583","Comparison of Alcohol and Steroid Injection for Treating Morton's Neuroma",[89],[3071],"Morton's Neuroma",[3052,3073,3074],"Injection of Alcohol into Foot","Injection of Lidocaine into Foot",{"intervention":3073,"totalTrials":92,"cells":3076},{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3081,"PHASE3":3083,"PHASE4":3085,"NA":3087},{"trials":3078,"activeCount":96},[],{"trials":3080,"activeCount":96},[],{"trials":3082,"activeCount":96},[],{"trials":3084,"activeCount":96},[],{"trials":3086,"activeCount":96},[],{"trials":3088,"activeCount":96},[3089],{"nctId":3067,"briefTitle":3068,"status":976,"phases":3090,"start":745,"enrollment":463,"conditions":3091,"interventions":3092},[89],[3071],[3052,3073,3074],{"intervention":3074,"totalTrials":92,"cells":3094},{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3101,"PHASE4":3103,"NA":3105},{"trials":3096,"activeCount":96},[],{"trials":3098,"activeCount":96},[],{"trials":3100,"activeCount":96},[],{"trials":3102,"activeCount":96},[],{"trials":3104,"activeCount":96},[],{"trials":3106,"activeCount":96},[3107],{"nctId":3067,"briefTitle":3068,"status":976,"phases":3108,"start":745,"enrollment":463,"conditions":3109,"interventions":3110},[89],[3071],[3052,3073,3074],{"intervention":3112,"totalTrials":92,"cells":3113},"Ghrelin",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3124},{"trials":3115,"activeCount":96},[],{"trials":3117,"activeCount":96},[],{"trials":3119,"activeCount":96},[],{"trials":3121,"activeCount":96},[],{"trials":3123,"activeCount":96},[],{"trials":3125,"activeCount":96},[3126],{"nctId":3127,"briefTitle":3128,"status":260,"phases":3129,"primaryCompletion":1003,"start":2260,"enrollment":3130,"conditions":3131,"interventions":3132},"NCT01190085","Effects of Ghrelin on Alcohol Cue Reactivity and Craving",[89],45,[748],[3112,3112,3133],"Saline solution",{"intervention":3133,"totalTrials":92,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3137,"activeCount":96},[],{"trials":3139,"activeCount":96},[],{"trials":3141,"activeCount":96},[],{"trials":3143,"activeCount":96},[],{"trials":3145,"activeCount":96},[],{"trials":3147,"activeCount":96},[3148],{"nctId":3127,"briefTitle":3128,"status":260,"phases":3149,"primaryCompletion":1003,"start":2260,"enrollment":3130,"conditions":3150,"interventions":3151},[89],[748],[3112,3112,3133],{"intervention":3153,"totalTrials":92,"cells":3154},"Tissue specimen",{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3156,"activeCount":96},[],{"trials":3158,"activeCount":96},[],{"trials":3160,"activeCount":96},[],{"trials":3162,"activeCount":96},[],{"trials":3164,"activeCount":96},[],{"trials":3166,"activeCount":96},[3167],{"nctId":3168,"briefTitle":3169,"status":260,"phases":3170,"primaryCompletion":900,"completion":900,"start":3171,"enrollment":16,"conditions":3172,"interventions":3174},"NCT01835925","Rectal Cancer Consortium",[],"2013-07",[3173],"Rectal Cancer",[3153],{"intervention":3176,"totalTrials":92,"cells":3177},"Alcohol, Ethyl",{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3179,"activeCount":96},[],{"trials":3181,"activeCount":96},[],{"trials":3183,"activeCount":96},[],{"trials":3185,"activeCount":96},[],{"trials":3187,"activeCount":96},[],{"trials":3189,"activeCount":96},[3190],{"nctId":3191,"briefTitle":3192,"status":260,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":3195,"enrollment":3196,"conditions":3197,"interventions":3199},"NCT03483389","Alcohol and Immune Response",[89],"2021-06-18","2018-10-01",76,[15,3198],"Alcohol; Harmful Use",[3176],{"intervention":3201,"totalTrials":92,"cells":3202},"Ethanol",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3204,"activeCount":96},[],{"trials":3206,"activeCount":96},[],{"trials":3208,"activeCount":96},[],{"trials":3210,"activeCount":96},[],{"trials":3212,"activeCount":96},[],{"trials":3214,"activeCount":96},[3215],{"nctId":3216,"briefTitle":3217,"status":260,"phases":3218,"primaryCompletion":3219,"completion":3219,"start":3220,"enrollment":198,"conditions":3221,"interventions":3222},"NCT03370783","Acute Neuroimmune Effects of Alcohol Using Free Water Imaging",[89],"2017-09-28","2017-03-31",[15],[3201]]